Download PDF
Planta Med 2010; 76(13): 1405-1410
DOI: 10.1055/s-0029-1240954
Pharmacology
Original Papers
© Georg Thieme Verlag KG Stuttgart · New York

A New Digitized Method of the Compulsive Gnawing Test Revealed Dopaminergic Activity of Salvinorin A In Vivo [*]

Stephen M. Phipps1 , Veronika Butterweck1
  • 1Department of Pharmaceutics, College of Pharmacy, University of Florida, Gainesville, Florida, USA
Further Information

Publication History

received January 2, 2010 revised January 30, 2010

accepted February 7, 2010

Publication Date:
09 March 2010 (online)

Also available at
    Permissions and Reprints

Abstract

The compulsive gnawing (CG) test has been used for numerous years as an assay to determine the dopaminergic activity of various compounds. We developed a new method of quantification via a digitization step which allowed a more precise measurement of the gnawing activity. It was the aim of the present study to explore possible dopaminergic effects of salvinorin A (SA), the major active compound of Salvia divinorum, using the new digitized CG test. A group of experiments using male C57BL/6 mice were performed to validate the new method of quantification showing only significant increases of gnawing when the dopamine reuptake inhibitors buproprion (20 mg/kg, p. o.) and nomifensine (10 mg/kg, i. p.) were given concomitantly with apomorphine (10 mg/kg, i. p.). Different concentrations of the SA (1.0, 2.5, 5, and 10 mg/kg, i. p.) were tested with positive dopaminergic activity when administered with apomorphine which differed from the semisynthetic counterpart U-69593. Furthermore, the activity observed with SA was unsuccessfully antagonized by the κ-opioid receptor antagonist norbinaltorphimine (NorBNI; 10 and 20 mg/kg, i. p.), while the dopamine antagonist haloperidol did successfully block (0.06 mg/kg, i. p.) the gnawing activity seen with SA. Our data further strengthen the argument that salvinorin A is not a selective κ-opioid receptor agonist and is the first in vivo study that veers from salvinorin A acting solely like its synthetic counterparts. Furthermore, the digitized CG test system used in this study provides a new computational method to accurately detect behavior associated with dopaminergic neurotransmission.

Key words

Salvia divinorum - Lamiaceae - salvinorin A - compulsive gnawing - dopaminergic activity - κ‐opioid receptor

1 Dedicated to Professor Dr. Dr. Adolf Nahrstedt on the occasion of his 70th birthday.

References

  • 1 Canales J J, Gilmour G, Iversen S D. The role of nigral and thalamic output pathways in the expression of oral stereotypies induced by amphetamine injections into the striatum.  Brain Res. 2000;  856 176-183
    CrossrefPubMedGoogle Scholar
  • 2 Karlsson R M, Hefner K R, Sibley D R, Holmes A. Comparison of dopamine D1 and D5 receptor knockout mice for cocaine locomotor sensitization.  Psychopharmacology (Berl). 2008;  200 117-127
    CrossrefPubMedGoogle Scholar
  • 3 Taha E B, Redgrave P. Neuroleptic suppression of feeding and oral stereotypy following microinjections of carbachol into substantia nigra.  Neurosci Lett. 1980;  20 357-361
    CrossrefPubMedGoogle Scholar
  • 4 Ther L, Schramm H. Apomorphine synergism (induced gnawing in mice) as a test for the differentiation of psychotropic substances.  Arch Int Pharmacodyn Ther. 1962;  138 302-310
    PubMedGoogle Scholar
  • 5 Ernst A M. Mode of action of apomorphine and dexamphetamine on gnawing compulsion in rats.  Psychopharmacologia. 1967;  10 316-323
    CrossrefPubMedGoogle Scholar
  • 6 Pedersen V. Potentiation of apomorphine effect (compulsive gnawing behaviour) in mice.  Acta Pharmacol Toxicol (Copenh). 1967;  25 (Suppl. 4) 63
    PubMedGoogle Scholar
  • 7 De Feo G, Lisciani R, Pavan L, Samarelli M, Valeri P. Possible dopaminergic involvement in biting compulsion induced by large doses of clonidine.  Pharmacol Res Commun. 1983;  15 613-619
    CrossrefPubMedGoogle Scholar
  • 8 Hedley L R, Wallach M B. Potentiation of apomorphine-induced gnawing in mice.  Prog Neuropsychopharmacol Biol Psychiatry. 1983;  7 47-56
    CrossrefPubMedGoogle Scholar
  • 9 Ernst A M. Compulsive gnawing.  Pharmacol Ther. 1976;  2 173-184
    PubMedGoogle Scholar
  • 10 Vogel H G. Drug discovery and evaluations: pharmacological assays, 2nd edition. Berlin; Springer-Verlag 2002: 567
    PubMedGoogle Scholar
  • 11 Roth B L, Baner K, Westkaemper R, Siebert D, Rice K C, Steinberg S, Ernsberger P, Rothmann R B. Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist.  Proc Natl Acad Sci USA. 2002;  99 11934-11939
    CrossrefPubMedGoogle Scholar
  • 12 Seeman P, Guan H C, Hirbec H. Dopamine D2High receptors stimulated by phencyclidines, lysergic acid diethylamide, salvinorin A, and modafinil.  Synapse. 2009;  63 698-704
    CrossrefPubMedGoogle Scholar
  • 13 Grundmann O, Phipps S M, Zadezensky I, Butterweck V. Salvia divinorum and salvinorin A: an update on pharmacology and analytical methodology.  Planta Med. 2007;  73 1039-1046
    Article in Thieme ConnectPubMedGoogle Scholar
  • 14 Butelman E R, Harris T J, Kreek M J. The plant-derived hallucinogen salvinorin A produces kappa-opioid agonist-like discriminative effects in rhesus monkeys.  Psychopharmacology (Berl). 2004;  172 220-224
    CrossrefPubMedGoogle Scholar
  • 15 Willmore-Fordham C B, Krall D M, McCurdy C R, Kinder D H. The hallucinogen derived from Salvia divinorum, salvinorin A, has kappa-opioid agonist discriminative stimulus effects in rats.  Neuropharmacology. 2007;  53 481-486
    CrossrefPubMedGoogle Scholar
  • 16 Baker L E, Panos J J, Killinger B A, Peet M M, Bell L M, Haliw L A, Walker S L. Comparison of the discriminative stimulus effects of salvinorin A and its derivatives to U69,593 and U50,488 in rats.  Psychopharmacology (Berl). 2009;  203 203-211
    CrossrefPubMedGoogle Scholar
  • 17 Braida D, Capurro V, Zani A, Rubino T, Vigano D, Parolaro D, Sala M. Potential anxiolytic- and antidepressant-like effects of salvinorin A, the main active ingredient of Salvia divinorum, in rodents.  Br J Pharmacol. 2009;  157 844-853
    CrossrefPubMedGoogle Scholar
  • 18 Tang A H, Code R A. Discriminative stimulus properties of nalorphine in the rhesus monkeys.  J Pharmacol Exp Ther. 1983;  227 563-569
    PubMedGoogle Scholar
  • 19 Siebert D J. Salvia divinorum and salvinorin A: new pharmacologic findings.  J Ethnopharmacol. 1994;  43 53-56
    CrossrefPubMedGoogle Scholar
  • 20 Weber C C, Eckert G P, Mueller W E. Effects of antidepressants on the brain/plasma distribution of corticosterone.  Neuropsychopharmacology. 2006;  31 2443-2448
    CrossrefPubMedGoogle Scholar
  • 21 Rojas-Corrales M O, Berrocoso E, Gibert-Rahola J, Mico J A. Antidepressant-like effect of tramadol and its enantiomers in reserpinized mice: comparative study with desipramine, fluvoxamine, venlafaxine and opiates.  J Psychopharmacol. 2004;  18 404-411
    CrossrefPubMedGoogle Scholar
  • 22 Redolat R, Vidal J, Gomez M C, Carrasco M C. Effects of acute bupropion administration on locomotor activity in adolescent and adult mice.  Behav Pharmacol. 2005;  16 59-62
    CrossrefPubMedGoogle Scholar
  • 23 Mague S D, Pliakas A M, Todtenkopf M S, Tomasiewicz H C, Zhang Y, Stevens W C, Jones R M, Portoghese P S, Carlezon W A. Antidepressant-like effects of kappa-opioid receptor antagonists in the forced swim test in rats.  J Pharmacol Exp Ther. 2003;  305 323-330
    CrossrefPubMedGoogle Scholar
  • 24 Sotnikova T D, Beaulieu J M, Barak L S, Wetsel W C, Caron M G, Gainetdinov R R. Dopamine-independent locomotor actions of amphetamines in a novel acute mouse model of Parkinson disease.  PLoS Biol. 2005;  3 e271
    CrossrefPubMedGoogle Scholar
  • 25 McKerchar T L, Fowler S C. Dissimilar effects of subchronic clozapine and haloperidol on operant lever pressing in C57BL/6J, BALB/cJ, and LP/J mice.  Behav Pharmacol. 2005;  16 585-589
    CrossrefPubMedGoogle Scholar
  • 26 McCurdy C R, Sufka K J, Smith G H, Warnick J E, Nieto M J. Antinociceptive profile of salvinorin A, a structurally unique kappa opioid receptor agonist.  Pharmacol Biochem Behav. 2006;  83 109-113
    CrossrefPubMedGoogle Scholar
  • 27 Moss D E, McMaster S B, Castaneda E, Johnson R L. An automated method for studying stereotyped gnawing.  Psychopharmacology (Berl). 1980;  69 267-269
    CrossrefPubMedGoogle Scholar
  • 28 Christensen A V, Fjalland B, Nielsen I M. On the supersensitivity of dopamine receptors, induced by neuroleptics.  Psychopharmacology (Berl). 1976;  48 1-6
    CrossrefPubMedGoogle Scholar
  • 29 Zhang Y, Butelman E R, Schlussman S D, Ho A, Kreek M J. Effects of the plant-derived hallucinogen salvinorin A on basal dopamine levels in the caudate putamen and in a conditioned place aversion assay in mice: agonist actions at kappa opioid receptors.  Psychopharmacology (Berl). 2005;  179 551-558
    CrossrefPubMedGoogle Scholar
  • 30 Thompson A C, Zapata A, Justice Jr J B, Vaughan R A, Sharpe L G, Shippenberg T S. Kappa-opioid receptor activation modifies dopamine uptake in the nucleus accumbens and opposes the effects of cocaine.  J Neurosci. 2000;  20 9333-9340
    PubMedGoogle Scholar
  • 31 Gehrke B J, Chefer V I, Shippenberg T S. Effects of acute and repeated administration of salvinorin A on dopamine function in the rat dorsal striatum.  Psychopharmacology (Berl). 2008;  197 509-517
    CrossrefPubMedGoogle Scholar
  • 32 Beerepoot P, Lam V, Luu A, Tsoi B, Siebert D, Szectman H. Effects of salvinorin A on locomotor sensitization to D2/D3 dopamine agonist quinpirole.  Neurosci Lett. 2008;  446 101-104
    CrossrefPubMedGoogle Scholar
  • 33 Perreault M L, Graham D, Scattolon S, Wang Y, Szechtman H, Foster J A. Cotreatment with the kappa opioid agonist U69593 enhances locomotor sensitization to the D2/D3 dopamine agonist quinpirole and alters dopamine D2 receptor and prodynorphin mRNA expression in rats.  Psychopharmacology (Berl). 2007;  194 485-496
    CrossrefPubMedGoogle Scholar
  • 34 Delfs J M, Kelley A E. The role of D1 and D2 dopamine receptors in oral stereotypy induced by dopaminergic stimulation of the ventrolateral striatum.  Neurosci Lett. 1990;  39 59-67
    PubMedGoogle Scholar
  • 35 Dadkar N K, Dohadwalla A N, Bhattacharva B K. The involvement of serotoninergic and noradrenergic systems in the compulsive gnawing in mice induced by imipramine and apomorphine.  J Pharm Pharmacol. 1976;  28 68-69
    PubMedGoogle Scholar
  • 36 Schoffelmeer A N, Hogenboom F, Mulder A H. Kappa1- and kappa2-opioid receptors mediating presynaptic inhibition of dopamine and acetylcholine release in rat neostriatum.  Br J Pharmacol. 1997;  122 520-524
    CrossrefPubMedGoogle Scholar

1 Dedicated to Professor Dr. Dr. Adolf Nahrstedt on the occasion of his 70th birthday.

Dr. Veronika Butterweck

Department of Pharmaceutics
University of Florida

Box 100494

Gainesville, FL 32610–0494

USA

Phone: + 1 35 22 73 78 25

Fax: + 1 35 22 73

Email: butterwk@cop.ufl.edu